262 related articles for article (PubMed ID: 29478824)
1. An unexpected player in Gaucher disease: The multiple roles of complement in disease development.
Pandey MK; Grabowski GA; Köhl J
Semin Immunol; 2018 Jun; 37():30-42. PubMed ID: 29478824
[TBL] [Abstract][Full Text] [Related]
2. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.
Pandey MK; Burrow TA; Rani R; Martin LJ; Witte D; Setchell KD; Mckay MA; Magnusen AF; Zhang W; Liou B; Köhl J; Grabowski GA
Nature; 2017 Mar; 543(7643):108-112. PubMed ID: 28225753
[TBL] [Abstract][Full Text] [Related]
3. C5a Activates a Pro-Inflammatory Gene Expression Profile in Human Gaucher iPSC-Derived Macrophages.
Serfecz JC; Saadin A; Santiago CP; Zhang Y; Bentzen SM; Vogel SN; Feldman RA
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576075
[TBL] [Abstract][Full Text] [Related]
4. The critical role of C5a as an initiator of neutrophil-mediated autoimmune inflammation of the joint and skin.
Sadik CD; Miyabe Y; Sezin T; Luster AD
Semin Immunol; 2018 Jun; 37():21-29. PubMed ID: 29602515
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting the C5-C5a receptor axis.
Woodruff TM; Nandakumar KS; Tedesco F
Mol Immunol; 2011 Aug; 48(14):1631-42. PubMed ID: 21549429
[TBL] [Abstract][Full Text] [Related]
6. Complement C5a Induces Pro-inflammatory Microvesicle Shedding in Severely Injured Patients.
Karasu E; Demmelmaier J; Kellermann S; Holzmann K; Köhl J; Schmidt CQ; Kalbitz M; Gebhard F; Huber-Lang MS; Halbgebauer R
Front Immunol; 2020; 11():1789. PubMed ID: 32983087
[TBL] [Abstract][Full Text] [Related]
7. Complement C5aR1 Signaling Promotes Polarization and Proliferation of Embryonic Neural Progenitor Cells through PKCζ.
Coulthard LG; Hawksworth OA; Li R; Balachandran A; Lee JD; Sepehrband F; Kurniawan N; Jeanes A; Simmons DG; Wolvetang E; Woodruff TM
J Neurosci; 2017 May; 37(22):5395-5407. PubMed ID: 28455369
[TBL] [Abstract][Full Text] [Related]
8. Complement C5a Receptor 1 Exacerbates the Pathophysiology of
Herrmann JB; Muenstermann M; Strobel L; Schubert-Unkmeir A; Woodruff TM; Gray-Owen SD; Klos A; Johswich KO
mBio; 2018 Jan; 9(1):. PubMed ID: 29362231
[TBL] [Abstract][Full Text] [Related]
9. Emerging therapeutic targets for Gaucher disease.
Vitner EB; Vardi A; Cox TM; Futerman AH
Expert Opin Ther Targets; 2015 Mar; 19(3):321-34. PubMed ID: 25416676
[TBL] [Abstract][Full Text] [Related]
10. A novel interpretation of immune redundancy and duality in reperfusion injury with important implications for intervention in ischaemic disease.
Thrane AS; Skehan JD; Thrane PS
Med Hypotheses; 2007; 68(6):1363-70. PubMed ID: 17169498
[TBL] [Abstract][Full Text] [Related]
11. Glucocerebrosidase, a new player changing the old rules in Lewy body diseases.
Yang NY; Lee YN; Lee HJ; Kim YS; Lee SJ
Biol Chem; 2013 Jul; 394(7):807-18. PubMed ID: 23435096
[TBL] [Abstract][Full Text] [Related]
12. Distinct roles of the anaphylatoxins C3a and C5a in dendritic cell-mediated allergic asthma.
Engelke C; Wiese AV; Schmudde I; Ender F; Ströver HA; Vollbrandt T; König P; Laumonnier Y; Köhl J
J Immunol; 2014 Dec; 193(11):5387-401. PubMed ID: 25355927
[TBL] [Abstract][Full Text] [Related]
13. New concepts on the therapeutic control of complement anaphylatoxin receptors.
Hawksworth OA; Li XX; Coulthard LG; Wolvetang EJ; Woodruff TM
Mol Immunol; 2017 Sep; 89():36-43. PubMed ID: 28576324
[TBL] [Abstract][Full Text] [Related]
14. Anaphylatoxin receptor promiscuity for commonly used complement C5a peptide agonists.
Li XX; Clark RJ; Woodruff TM
Int Immunopharmacol; 2021 Nov; 100():108074. PubMed ID: 34454293
[TBL] [Abstract][Full Text] [Related]
15. Assessment of cellular cobalamin metabolism in Gaucher disease.
Basgalupp SP; Siebert M; Ferreira C; Behringer S; Spiekerkoetter U; Hannibal L; Schwartz IVD
BMC Med Genet; 2020 Jan; 21(1):12. PubMed ID: 31931749
[TBL] [Abstract][Full Text] [Related]
16. C5a-C5aR1 Axis Activation Drives Envenomation Immunopathology by the Snake
Silva de França F; Villas-Boas IM; Cogliati B; Woodruff TM; Reis EDS; Lambris JD; Tambourgi DV
Front Immunol; 2021; 12():652242. PubMed ID: 33936074
[TBL] [Abstract][Full Text] [Related]
17. The metabolism of glucocerebrosides - From 1965 to the present.
Futerman AH; Platt FM
Mol Genet Metab; 2017; 120(1-2):22-26. PubMed ID: 27955980
[TBL] [Abstract][Full Text] [Related]
18. C-X-C Motif Chemokine Ligand 9 and Its CXCR3 Receptor Are the Salt and Pepper for T Cells Trafficking in a Mouse Model of Gaucher Disease.
Magnusen AF; Rani R; McKay MA; Hatton SL; Nyamajenjere TC; Magnusen DNA; Köhl J; Grabowski GA; Pandey MK
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884512
[TBL] [Abstract][Full Text] [Related]
19. Functional and genetic characterization of the non-lysosomal glucosylceramidase 2 as a modifier for Gaucher disease.
Yildiz Y; Hoffmann P; Vom Dahl S; Breiden B; Sandhoff R; Niederau C; Horwitz M; Karlsson S; Filocamo M; Elstein D; Beck M; Sandhoff K; Mengel E; Gonzalez MC; Nöthen MM; Sidransky E; Zimran A; Mattheisen M
Orphanet J Rare Dis; 2013 Sep; 8():151. PubMed ID: 24070122
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of anaphylatoxin C5a on antigen presenting cells, roles for C5aR1 and C5aR2.
Zaal A; van Ham SM; Ten Brinke A
Immunol Lett; 2019 May; 209():45-52. PubMed ID: 30959077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
